Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient

Journal of Alzheimer's Disease

Volumn 24, Issue 2, 2011, Pages 315-325

  Roher, Alex E ^a   Maarouf, Chera L ^a   Daugs, Ian D ^a   Kokjohn, Tyler A ^a,b   Hunter, Jesse M ^a   Sabbagh, Marwan N ^a   Beach, Thomas G ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Active immunotherapy; Alzheimer's disease; amyloid plaques; amyloid ; bapineuzumab; cerebral amyloid angiopathy; neurofibrillary tangles; passive immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BAPINEUZUMAB; DEXAMETHASONE; DONEPEZIL; EPITOPE; PLACEBO; RIVASTIGMINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ASTHMA; ATAXIA; BASAL GANGLION; BRAIN ATHEROSCLEROSIS; BRAIN CIRCULUS ARTERIOSUS; BRAIN EDEMA; BRAIN INFARCTION; BRAIN WEIGHT; CASE REPORT; CAUDATE NUCLEUS; CAUSE OF DEATH; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR ACCIDENT; CHEMICAL ANALYSIS; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DEMENTIA; DEPIGMENTATION; DEPRESSION; DRUG CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; ENTORHINAL CORTEX; EPILEPTIC DISCHARGE; FAMILY HISTORY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; GAIT DISORDER; GASTROINTESTINAL REFLUX; GLIOSIS; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOREACTIVITY; IMMUNOTHERAPY; LEPTOMENINX; LEUKOCYTE; MALE; MAMMILLARY BODY; MEDICAL HISTORY; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PURKINJE CELL; PUTAMEN; SUBSTANTIA NIGRA; SUBTHALAMUS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WHITE MATTER;

EID: 79955607727     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101809     Document Type: Article

References (45)

1. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L (1997) Amyloid precur-sor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci US A 94, 1550-1555.
2. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) A phase 2 multiple ascend-ing dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
3. -(1997) Consensus recommendations for the postmortem diag-nosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Dis-ease. Neurobiol Aging 18, S1-S2.
4. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43, 250-260.
5. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-TortosaE, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
6. Maarouf CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Masliah E, Nicoll JA, Sabbagh MN, Beach TG, Castano EM, Roher AE (2010) The biochemical after-math of anti-amyloid immunotherapy. Mol Neurodegener 5, 39.
7. Mirra SS (1997) The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 18, S91-S94. (Pubitemid 27454705)
8. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
9. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9, 229-245.
10. Esh C, Patton L, Kalback W, Kokjohn TA, Lopez J, Brune D, Newell AJ, Beach T, Schenk D, Games D, Paul S, Bales K, Ghetti B, Castano EM, Roher AE (2005) Altered APP pro-cessing in PDAPP (Val717- Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry 44, 13807-13819. (Pubitemid 41507461)
11. Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Patton RL, Kalback WM, Luehrs DC, Walker DG, Castano EM, Beach TG, Ghetti B, Roher AE (2008) Histopathological and molecular heterogeneity among individuals with Dementia associated with Presenilin mutations. Mol Neurodegener 3, 20.
12. Mulugeta E, Molina-Holgado F, Elliott MS, Hortobagyi T, Perry R, Kalaria RN, Ballard CG, Francis PT (2008) Inflam-matory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement Geriatr CognDisord 25,278-286. (Pubitemid 351363893)
13. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN (1996) Apolipoprotein E-epsilon4 alleles in cerebral amy-loid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 148, 2083-2095.
14. Wolk DA, Dickerson BC (2010) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl AcadSci USA 107, 10256-10261.
15. Lopez OL, Hamilton R, Ikonomovic M, Mathis CA, Price JA, Becker JT, Saxton JA, Dekosky ST, Klunk WE (2009) In vivo amyloid deposition and neuropathological findings after humanized amyloid ß-specific monoclonal antibodies therapy in a patient with Alzheimer's disease. Alzheimers Dement 5, P64-P65.
16. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. LancetNeurol 9, 363-372.
17. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C (2006) Abeta species removal after Abeta42 immunization. J Neuropathol Exp Neurol 65, 1040-1048. (Pubitemid 44684661)
18. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of enceph-alitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14, 11-20. (Pubitemid 38200585)
19. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, SchenkD (2005) Abeta vaccina-tion effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131. (Pubitemid 40082949)
20. Patton RL, Kalback WM, Esh CL, Kokjohn TA, van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castano EM, Roher AE (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 169, 1048-1063. (Pubitemid 44411966)
21. Boche D, Denham N, Holmes C, Nicoll JA (2010) Neu-ropathology after active Abeta42 immunotherapy: implica-tions for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384.
22. Webster S, Bonnell B, Rogers J (1997) Charge-based binding of complement component C1 q to the Alzheimer amyloid beta-peptide. AmJ Pathol 150, 1531-1536. (Pubitemid 27193802)
23. Emmerling MR, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Roher AE, Raby CA (2000) Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury. Ann N Y Acad Sci 903, 118-122. (Pubitemid 30251547)
24. Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, Yoshimura M, Sugihara S, Ihara Y (2000) Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 157, 2093-2099.
25. Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J, Kirkpatrick J, Kuo YM, Roher AE (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci 16, 6021-6037. (Pubitemid 26313978)
26. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE (1998) The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 273, 29719-29726. (Pubitemid 28509983)
27. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE (1998) Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. Mol Med 4, 480-489. (Pubitemid 28419092)
28. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ (1993) beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 90, 10836-10840.
29. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D, Basi G, Schenk D, Seubert P, Games D (2008) Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 28, 6787-6793.
30. Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI (2010) Struc-tural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem 285, 3417-3427.
31. Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, Kling K, Schenk D, Johnson-Wood K, Schroeter S, Gill D, Jacobsen JS, Pangalos M, Basi G, Games D (2008) Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurode-generDis 5, 65-71.
32. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE (2002) APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41, 922-928. (Pubitemid 34061994)
33. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mousemodelof Alzheimer'sdisease.JNeurosci21,372-381. (Pubitemid 32107428)
34. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268, 3072-3083. (Pubitemid 23070928)
35. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R (2005) Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 44, 10810-10821. (Pubitemid 41153641)
36. Roher AE, Kokjohn TA, Esh C, Weiss N, Childress J, Kalback W, Luehrs DC, Lopez J, Brune D, Kuo YM, Farlow M, Murrell J, Vidal R, Ghetti B (2004) The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. J Biol Chem 279, 5829-5836. (Pubitemid 38220614)
37. Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E (2005) Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impair-ment. Clin Chem 51, 1650-1660. (Pubitemid 41233100)
38. Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David JP, Vanmechelen E, Sergheraert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. JNeurochem85, 1581-1591. (Pubitemid 36702570)
39. Harigaya Y, Shoji M, Kawarabayashi T, Kanai M, Nakamura T, Iizuka T, Igeta Y, Saido TC, Sahara N, Mori H, Hirai S (1995) Modified amyloid beta protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 211, 1015-1022.
40. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK (1997) Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409, 411-416. (Pubitemid 27285896)
41. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE (1997) Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237, 188-191. (Pubitemid 27390349)
42. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, LalR (2010) Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci USA 107, 6538-6543.
43. Wei W, Norton DD, Wang X, Kusiak JW (2002) Abeta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125, 2036-2043.
44. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ (1994) Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269, 10987-10990.
45. Jellinger KA (2010) Con: Can neuropathology really confirm the exact diagnosis? Alzheimers Res Ther 2, 11.